CNBCâs Angelica Peebles and Eli Lilly chairman and CEO David Ricks join âSquawk on the Streetâ to discuss results of the companyâs 3-year obesity study, which showed its highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo.